Rui Jing Jiang W'18
Rui Jing Jiang is the Founder and CEO of Avisi Technologies, Inc., a company developing a nanotechnology-enabled ocular implant called VisiPlate. VisiPlate is 20x thinner than a single human hair and aims to treat patients with glaucoma, the leading cause of irreversible blindness worldwide. Glaucoma is an irreversible and oftentimes asymptomatic disease, affecting over 140 million people worldwide. There are over 4 million patients in the US today. VisiPlate has demonstrated competitive effectiveness and safety in pre-clinical animal models and is currently in first-in-human clinical trial investigations.
Rui Jing is a proud member of AdvaMed (Advanced Medical Technology Association) and serves as a panel reviewer for the National Science Foundation Small Business Innovation Research (SBIR) program. Rui Jing is also part of the Nano Entrepreneurship Network by the US National Nanotechnology Initiative. Rui Jing has spearheaded Avisi’s growth since founding the company in 2017 and was recognized as one of Philadelphia’s Inno Under 25 by Philadelphia Business Journal. Rui Jing graduated from Wharton at the University of Pennsylvania with a B.S. in Economics, Finance, and Strategic Management.
Avisi Technologies has been funded by investors including Accanto, Good Growth Capital, Mountain State Capital, Ben Franklin Technology Partners, Quaker Capital, Grays Ferry Capital, the University of Pennsylvania, and the National Science Foundation (Phase I and Phase II SBIRs). Avisi is a Johnson & Johnson JLABS company, a MedTech Innovator Accelerator company, and a UCSF Rosenman Innovator. In 2018, Avisi was awarded the University of Pennsylvania President’s Innovation Prize. Since then, Avisi has been recognized as a finalist of the 2022 Fierce Life Sciences Innovation Awards, one of the ten most promising Philadelphia tech companies of the decade by Technical.ly’s RealLIST Startups, a Watchlist venture in Wharton Magazine, and a finalist at the 2019 SXSW Innovation Awards for Health, Med, and Biotech
[Back to VIP EIR Page]
Rui Jing is a proud member of AdvaMed (Advanced Medical Technology Association) and serves as a panel reviewer for the National Science Foundation Small Business Innovation Research (SBIR) program. Rui Jing is also part of the Nano Entrepreneurship Network by the US National Nanotechnology Initiative. Rui Jing has spearheaded Avisi’s growth since founding the company in 2017 and was recognized as one of Philadelphia’s Inno Under 25 by Philadelphia Business Journal. Rui Jing graduated from Wharton at the University of Pennsylvania with a B.S. in Economics, Finance, and Strategic Management.
Avisi Technologies has been funded by investors including Accanto, Good Growth Capital, Mountain State Capital, Ben Franklin Technology Partners, Quaker Capital, Grays Ferry Capital, the University of Pennsylvania, and the National Science Foundation (Phase I and Phase II SBIRs). Avisi is a Johnson & Johnson JLABS company, a MedTech Innovator Accelerator company, and a UCSF Rosenman Innovator. In 2018, Avisi was awarded the University of Pennsylvania President’s Innovation Prize. Since then, Avisi has been recognized as a finalist of the 2022 Fierce Life Sciences Innovation Awards, one of the ten most promising Philadelphia tech companies of the decade by Technical.ly’s RealLIST Startups, a Watchlist venture in Wharton Magazine, and a finalist at the 2019 SXSW Innovation Awards for Health, Med, and Biotech
[Back to VIP EIR Page]